Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B E Hansen

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Gut|June 1, 2005
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapyH J Flink, D Sprengers, B E Hansen, et al.
The Netherlands Journal of Medicine|January 27, 2012
Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patientsC D M Witjes, J N M IJzermans, A A van der Eijk, et al.
Journal of Viral Hepatitis|January 30, 2009
On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeksJ G P Reijnders, W F Leemans, B E Hansen, et al.
Journal of Hepatology|May 1, 1997
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centersS W Schalm, B E Hansen, L Chemello, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2005
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis CB J Veldt, B E Hansen, M J C Eijkemans, et al.
Journal of Hepatology|August 24, 1999
Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study GroupH J van Hoogstraten, B E Hansen, H R van Buuren, et al.
Molecular Therapy. Nucleic Acids|January 30, 2017
A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective CohortW K Utomo, L H Looijenga, M J Bruno, et al.
The Journal of Experimental Medicine|April 19, 2000
Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complexM Krogsgaard, K W Wucherpfennig, B Cannella, et al.
Journal of Viral Hepatitis|April 10, 2013
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analoguesR Zoutendijk, M J Sonneveld, J G P Reijnders, et al.
The Journal of Infectious Diseases|November 6, 2004
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study groupA Mocroft, B Ledergerber, J P Viard, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Gut|June 1, 2005
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapyH J Flink, D Sprengers, B E Hansen, et al.
The Netherlands Journal of Medicine|January 27, 2012
Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patientsC D M Witjes, J N M IJzermans, A A van der Eijk, et al.
Journal of Viral Hepatitis|January 30, 2009
On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeksJ G P Reijnders, W F Leemans, B E Hansen, et al.
Journal of Hepatology|May 1, 1997
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centersS W Schalm, B E Hansen, L Chemello, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2005
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis CB J Veldt, B E Hansen, M J C Eijkemans, et al.
Journal of Hepatology|August 24, 1999
Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study GroupH J van Hoogstraten, B E Hansen, H R van Buuren, et al.
Molecular Therapy. Nucleic Acids|January 30, 2017
A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective CohortW K Utomo, L H Looijenga, M J Bruno, et al.
The Journal of Experimental Medicine|April 19, 2000
Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complexM Krogsgaard, K W Wucherpfennig, B Cannella, et al.
Journal of Viral Hepatitis|April 10, 2013
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analoguesR Zoutendijk, M J Sonneveld, J G P Reijnders, et al.
The Journal of Infectious Diseases|November 6, 2004
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study groupA Mocroft, B Ledergerber, J P Viard, et al.
Pageof 8